{"generic":"Desoxycholic Acid","drugs":["Desoxycholic Acid","Kybella"],"mono":{"0":{"id":"928217-s-0","title":"Generic Names","mono":"Desoxycholic Acid"},"1":{"id":"928217-s-1","title":"Dosing and Indications","sub":[{"id":"928217-s-1-4","title":"Adult Dosing","mono":"<b>Excess subcutaneous fat of submental region:<\/b> 0.2 mL subQ injection into the submental area; space injections 1 cm apart; maximum of 50 injections or 10 mL; provides a dose of 2 mg\/cm(2); may repeat treatment up to 6 times at intervals of no less than 1 month "},{"id":"928217-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in pediatric patients "},{"id":"928217-s-1-6","title":"Dose Adjustments","mono":"<b>Geriatric:<\/b> Start at lower end of dosing range."},{"id":"928217-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Excess subcutaneous fat of submental region<br\/>"}]},"3":{"id":"928217-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928217-s-3-9","title":"Contraindications","mono":"Infection at injection site <br\/>"},{"id":"928217-s-3-10","title":"Precautions","mono":"<ul><li>Dermatologic:<\/li><li>-- Hematoma\/bruising at the injection site has been reported<\/li><li>-- Tissue damage may occur; avoid injection into or in close proximity to salivary glands, lymph nodes, or muscles<\/li><li>Gastrointestinal:<\/li><li>-- Dysphagia has been reported; avoid use in patients with current or past history of dysphagia<\/li><li>Hematologic:<\/li><li>-- Bleeding abnormalities or concurrent antiplatelet or anticoagulant therapy; increased risk of excessive bleeding or bruising at injection site<\/li><li>Neurologic:<\/li><li>-- Marginal mandibular nerve injuries have been reported; do not inject into or in close proximity to the marginal mandibular branch<\/li><li>Other:<\/li><li>-- Prior surgical or aesthetic treatment of submental area; scar tissue may impact safe administration<\/li><\/ul>"},{"id":"928217-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"928217-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928217-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema<\/li><li><b>Dermatologic:<\/b>Erythema (27%), Induration at injection site (23%), Injection site pain (70%), Numbness, Injection site (66%), Swelling, Injection site<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Contusion, Injection site, Nerve injury, Injection site (4%)<\/li><li><b>Gastrointestinal:<\/b>Dysphagia (2%)<\/li><li><b>Hematologic:<\/b>Hematoma, Injection site<\/li><\/ul>"},"6":{"id":"928217-s-6","title":"Drug Name Info","sub":{"0":{"id":"928217-s-6-17","title":"US Trade Names","mono":"Kybella<br\/>"},"2":{"id":"928217-s-6-19","title":"Class","mono":"Dermatological Agent<br\/>"},"3":{"id":"928217-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928217-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"928217-s-7","title":"Mechanism Of Action","mono":"Deoxycholic acid is a natural bile component and is cytolytic, destroying the cell membrane and causing lysis when injected into tissue.<br\/>"},"8":{"id":"928217-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"928217-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, SubQ: 18 minutes<\/li><li>Bioavailability, SubQ: Rapidly absorbed<\/li><\/ul>"},"1":{"id":"928217-s-8-24","title":"Distribution","mono":"Protein binding: 98% <br\/>"},"3":{"id":"928217-s-8-26","title":"Excretion","mono":"Fecal: 100% as intact drug <br\/>"}}},"9":{"id":"928217-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>Do not dilute or admix with other compounds.<br\/><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>Each vial is for single-patient use only.<\/li><li>Palpate within the target treatment area to ensure sufficient submental fat and to identify subcutaneous fat between the dermis and platysma (ie, pre-platysmal fat).<\/li><li>Use a surgical pen to outline the planned treatment area.<\/li><li>Apply a 1-cm injection grid and mark the injection sites.<\/li><li>Draw 1 mL of deoxycholic acid into a 1-mL syringe using a large-bore needle; expel any air bubbles in the syringe.<\/li><li>Have the patient tense the platysma; pinch the submental fat and use a 30-gauge (or smaller), 0.5-inch needle to inject 0.2 mL of solution into the pre-platysmal fat next to each marked injection site.<\/li><li>Inject into the fat tissue within the target treatment area at a depth of about halfway into the subcutaneous fat layer.<\/li><li>Avoid intradermal injection and do not withdraw the needle from the subcutaneous fat during the injection; skin ulceration may occur from intradermal exposure to solution.<\/li><li>If resistance is met as the needle is inserted, withdraw to an appropriate depth prior to administering injection.<\/li><li>Do not inject solution above the inferior border of the mandible or into a region defined by a 1- to 1.5-cm line below the inferior border (from the angle of the mandible to the mentum).<\/li><li>Do not inject into or within close proximity (ie, 1 to 1.5 cm) to other tissues including muscle, salivary glands, and lymph nodes.<\/li><li>Ice or cold packs and topical or injectable local anesthesia, such as lidocaine, may be used to increase patient comfort.<\/li><li>Bleeding after needle withdrawal can be minimized by applying pressure to injection site.<\/li><li>Adhesive dressings may be used.<\/li><\/ul><\/li><\/ul>"},"10":{"id":"928217-s-10","title":"Monitoring","mono":"Improvement in convexity or fullness associated with submental fat indicates efficacy<br\/>"},"11":{"id":"928217-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>  Powder: 99 %<br\/>"},"13":{"id":"928217-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report symptoms of marginal mandibular nerve paresis or dysphasia.<\/li><li>Side effects may include injection site reactions such as edema, swelling, hematoma, pain, numbness, erythema, or induration.<\/li><\/ul>"}}}